Regor Pharmaceuticals
Regor Therapeutics Group is a clinical-stage biotechnology company dedicated to developing innovative medicines for oncology, metabolism, and auto-immunity. Leveraging its proprietary drug discovery engine, rCARD, the company rapidly prototypes and validates candidate molecules, aiming to address large unmet medical needs. With a strong scientific foundation and strategic collaborations, Regor strives to build a world-class innovation engine that promotes scientific excellence and teamwork.
Industries
Nr. of Employees
small (1-50)
Regor Pharmaceuticals
Patents
Products
RGT‑075
Orally bioavailable, once‑daily small‑molecule GLP‑1 receptor agonist undergoing clinical development for obesity (Phase IIb initiated; Phase II data reported).
Next‑generation CDK inhibitor programs (RGT‑419B / RGT‑587)
Oral next‑generation CDK inhibitor programs for breast cancer that have progressed to early clinical trials and have been subject to out‑licensing agreements with larger pharmaceutical partners.
RGT‑075
Orally bioavailable, once‑daily small‑molecule GLP‑1 receptor agonist undergoing clinical development for obesity (Phase IIb initiated; Phase II data reported).
Next‑generation CDK inhibitor programs (RGT‑419B / RGT‑587)
Oral next‑generation CDK inhibitor programs for breast cancer that have progressed to early clinical trials and have been subject to out‑licensing agreements with larger pharmaceutical partners.
Services
Collaborative engagements that apply the in‑house computational discovery engine and medicinal chemistry capabilities to identify, optimize, and out‑license preclinical candidates to pharmaceutical partners.
Collaborative engagements that apply the in‑house computational discovery engine and medicinal chemistry capabilities to identify, optimize, and out‑license preclinical candidates to pharmaceutical partners.
Expertise Areas
- Computationally enabled drug discovery
- Small‑molecule therapeutic development
- Structure‑based drug design
- Medicinal and process chemistry
Key Technologies
- Computational biology
- Computational chemistry
- Generative models for molecule design
- Structure‑based drug design
News & Updates
Regor will present data on its lead obesity candidate, RGT-075, at the ADA's 85th Scientific Sessions.
Regor and Sermonix announced a strategic collaboration to optimize the rCARD platform for target and therapeutic discovery.
Regor entered into an agreement with Genentech for the acquisition of its portfolio of next-generation CDK inhibitors for breast cancer.
Regor announced its participation in the Goldman Sachs Healthcare Conference.
Regor initiated a Phase 2 study of RGT-075, an oral GLP-1 receptor agonist, for obesity treatment.
Regor announced safety and efficacy data for RGT-419B in advanced breast cancer patients.
Regor will present data on its lead obesity candidate, RGT-075, at the ADA's 85th Scientific Sessions.
Regor and Sermonix announced a strategic collaboration to optimize the rCARD platform for target and therapeutic discovery.
Regor entered into an agreement with Genentech for the acquisition of its portfolio of next-generation CDK inhibitors for breast cancer.
Regor announced its participation in the Goldman Sachs Healthcare Conference.
Regor initiated a Phase 2 study of RGT-075, an oral GLP-1 receptor agonist, for obesity treatment.
Regor announced safety and efficacy data for RGT-419B in advanced breast cancer patients.